Phenotypic drug discovery (PDD) approaches do not rely on knowledge of the identity of a
specific drug target or a hypothesis about its role in disease, in contrast to the target-based …

There has been a resurgence of interest in the use of phenotypic screens in drug discovery
as an alternative to target-focused approaches. Given that oncology is currently the most …

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of
familial Parkinson’s disease (PD). Although biochemical studies have shown that certain PD …

In order to efficiently characterize both antiproliferative potency and mechanism of action of
small molecules targeting the cell cycle, we developed a high-throughput image-based …

There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors
of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is …

Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience
research community because it is one of the most compelling targets for a potential disease-…

The translational stop signal and polypeptide release factor (RF) complexed with
Escherichia coli ribosomes have been shown to be in close physical contact by site-directed …

Hematopoietic progenitor kinase 1 (HPK1) is implicated as a negative regulator of T-cell
receptor-induced T-cell activation. Studies using HPK1 kinase-dead knock-in animals have …

CDK4 and CDK6 are kinases with similar sequences that regulate cell cycle progression
and are validated targets in the treatment of cancer. Glioblastoma is characterized by a high …

Activation of the extracellular signal-regulated kinase-2 (ERK2) by phosphorylation has
been shown to involve changes in protein dynamics, as determined by hydrogen-deuterium …